Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors - Related Studies

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

This study has been completed.

Study NCT00039481. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition

2	Interventions listed in this trial
		cyclophosphamide
		dexrazoxane hydrochloride
		doxorubicin hydrochloride
		filgrastim
		oblimersen

3	Additional drug interventions recognized in this trial
		Doxorubicin
		Razoxane

4	More general drug interventions related to this trial
		Alkylating Agents
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Antineoplastic Agents, Alkylating
		Antirheumatic Agents
		Cardiovascular Agents
		Chelating Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Myeloablative Agonists
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

5	Sponsors listed in this trial
		Children's Oncology Group
		National Cancer Institute (NCI)